- Company
- Will P-CABs take over PPIs in GERD treatment market?
- by Whang, byung-woo May 12, 2021 05:58am
- With HK Inno.N’s K-Cab increasing its influence in the potassium-competitive acid blocker (P-CAB) market, the introduction of new P-CAB products raises the question of whether the products may increase the P-CABs' share in the market. In addition to Daewoong Pharmaceutical’s Fexuprazan, which is expected to be approved in Korea within this
- Company
- Trials to suspend refund negotiations for CA drugs fail
- by Chon, Seung-Hyun May 11, 2021 06:00am
- Once again, the pharmaceutical companies have failed to suspend the execution of negotiations for the retrieval of insurance that has been paid for 'choline alfoscerate.' Both of the trials that were filed by two groups of pharmaceutical companies against the health authorities in Korea were dismissed by the court. According to industry
- Company
- The cobas SARS-CoV-2 & Influenza A/B Test was approved
- by May 10, 2021 05:56am
- Roche Diagnostics Korea announced on the 6th that it has obtained permission from the MFDS to "cobas SARS-CoV-2 & Fluenza A/B," which can diagnose COVID-19 and flu at the same time. The cobas® SARS-CoV-2 & Influenza A/B Test is a multiplex reverse transcription polymerase chain reaction (RT-PCR) assay intended for simultaneous qualitative
- Company
- The trend to advertise vaccines is diversity and young men
- by May 7, 2021 06:02am
- Vaccine advertisements by pharmaceutical companies are diversifying. Instead of the flu vaccine, it has diversified into vaccines for rota virus, pneumococcus, cervical cancer, and whooping cough. This is to raise awareness of vaccinations for vaccines that have not been well-known until now as interest in preventing infectious diseases has i
- Company
- Cherry Huang to succeed Jenny Zheng as head of Janssen Korea
- by Eo, Yun-Ho May 7, 2021 06:01am
- Janssen will continue to have a foreign leader head its Korean subsidiary. According to industry sources, Janssen Korea has appointed Cherry Huang as the next CEO of Janssen Korea to take Jenny Zhuang’s place after Zhuang’s term ends in April. Cherry Huang, who is currently the CFO of Janssen Asia Pacific, will be leading Janssen Korea
- Company
- “Evenity is effective in patients at very-high-risk of OP"
- by May 7, 2021 06:01am
- The strategic paradigm for osteoporosis treatment has shifted. Compared to the past where not many patients were treated for osteoporosis and those who were treated used bone resorption inhibitors like bisphosphonate, a more aggressive treatment paradigm has landed in the field of osteoporosis treatment. The development of new drugs had tri
- Company
- Why SK and GC's deal for Xarelto exclusivity right misfired
- by Kim, Jin-Gu May 6, 2021 06:07am
- SK Chemicals's discussions with GC Pharma on handing over the exclusivity rights of Xarelto (rivaroxaban) had broken down in the end. The reason is known to be that the scope of the patent avoided by SK Chemicals does not match the composition of the generic developed by GC Pharma. According to industry sources on the 5th, the sale of the
- Company
- Moderna’s next steps in Korea…vaccine production scenarios
- by Kim, Jin-Gu May 6, 2021 06:07am
- The establishment of Moderna’s Korean subsidiary has begun. Moderna's business team from its U.S. headquarters had visited a factory of a domestic pharmaceutical company. The company's actions are adding strength to the speculation that domestic production of Moderna's vaccines is imminent. The factory that the business team had visite
- Company
- Eli Lilly applies for reimbursement of Emgality in Korea
- by Eo, Yun-Ho May 4, 2021 05:55am
- The new migraine treatment ‘Emgality’ is seeking reimbursement benefits in Korea. According to industry officials, Eli Lilly Korea has recently submitted a reimbursement application for its calcitonin gene-related peptide (CGRP)-targeted migraine prevention therapy ‘Emgality (galcanezumab).’ Emgality, the first CGRP-targeted migr
- Company
- Hanmi launched a new challenge for patent of Entresto
- by Kim, Jin-Gu May 3, 2021 05:54am
- Hanmi took a new challenge in patenting the heart failure treatment Entresto (Sacubitril/Valsartan). It was already challenging other patents and requested an invalidation trial for a more difficult patent. If Hanmi succeeds in overcoming its patent on its own, it is expected that it will be able to release generics earlier than other comp
